AI Hardware and Life Sciences Cloud: Long-Term Growth Outlook for NVDA and VEEV

Nvidia continues to solidify its leadership in the artificial intelligence sector, driven by robust financial performance and a roadmap of next-generation hardware. For investors with a long-term horizon, the shift toward 'agentic AI'—systems capable of autonomous planning and execution—represents a significant catalyst for enterprise spending. In fiscal year 2026, Nvidia reported revenue of $215.9 billion, a 65% year-over-year increase, with earnings per share rising 67% to $4.90. The company is preparing to launch the Vera Rubin platform in the second half of the year, succeeding the Blackwell AI computing platform. CEO Jensen Huang anticipates combined purchase orders for the Vera Rubin and Blackwell platforms to reach approximately $1 trillion through 2027. Simultaneously, Veeva Systems maintains a specialized moat within the life sciences industry. By focusing on regulatory compliance and clinical trial data integrity rather than generalist cloud services, the company has secured 15 of the top 20 global biopharma companies as clients. This specialization has created high switching costs, protecting the firm from broader market competition. From a valuation perspective, Nvidia's forward price-to-earnings ratio of 25.6 remains relatively aligned with the information technology sector average of 23.5. While growth stocks typically exhibit higher volatility, the fundamental demand for AI-driven productivity tools suggests a strong trajectory for both companies over the next five years.